10/533869

JC06 Dd PCT/PTO 05 MAY 20

I hereby certify that this con idence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV520562595US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Signature:

Docket No.: ASZD-P01-881 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Edman et al.

For:

Application No.: Not Yet Assigned

Filed: May 5, 2005

AN AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING THE THROMBIN INHIBITOR MELAGATRAN AND USE OF THE FORMULATION IN THE MANUFACTURE OF A MEDICAMENT FOR USE BY NASAL ADMINISTRATION IN TREATING THROMBOEMBOLISM

Confirmation No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450


Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A copy of each reference on the PTO/SB/08 is not attached with the exception of the International Search Report for PCT/SE2003/001738.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information



as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-881.

Dated: May 5, 2005

Respectfully submitted,

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

JC06 Rec'd PCT/PTO 05 MAY 2005

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	Not & et Assigned 2869	
l IN	IFORMATION	1 DI	SCLOSURE	Filing Date	May 5, 2005	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Peter Edman	
				Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-881	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number p	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
	No.1	Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear	
	AA	US-5,795,896	08-18-1998	Lofroth		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
	BA	WO-00/41716 A1	07-20-2000			Г		
	BB	WO-01/95932 A1	12-20-2001			Г		
	ВС	WO-97/45138 A1	12-04-1997					
	BD	WO-00/64470 A1	11-02-2000					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Initials No 1 magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher,		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	CA	Cecilia Wadell et al., "Permeability of porcine nasal mucosa correlated with human nasal absorption," European Journal of Pharmaceutical Sciences 18:47-53 (2003)				
	СВ	International Search Report from PCT/SE2003/001738 (02/10/2004)				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Dat	te	
Signature	1_	nsidered	
9.3		110100100	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.